Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H13NO3S2.C15H12NO3S2.C5H14NO |
Molecular Weight | 741.96 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O.CC(=C/C3=CC=CC=C3)\C=C4/SC(=S)N(CC([O-])=O)C4=O
InChI
InChIKey=WKSNHZZSMLFYFI-UROVXFGGSA-M
InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;
Molecular Formula | C5H13NO |
Molecular Weight | 103.1628 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H13NO3S2 |
Molecular Weight | 319.399 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/18447661
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18447661
Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P15121 Gene ID: 231.0 Gene Symbol: AKR1B1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/18447661 |
0.28 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | KINEDAK Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. | 1998 Jun |
|
Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. | 2001 Jun |
|
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. | 2011 Aug 15 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771994/
50 mg, 3 times/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12200074
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:36:42 UTC 2023
by
admin
on
Sat Dec 16 10:36:42 UTC 2023
|
Record UNII |
16AHE7410O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
117587644
Created by
admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
|
PRIMARY | |||
|
1665300-21-9
Created by
admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
|
PRIMARY | |||
|
16AHE7410O
Created by
admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |